FEMY FEMASYS INC

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, founder, president & chief executive officer, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest. The conference is being held virtually on June 20-22, 2023.

Kathy Lee-Sepsick will participate in a fireside chat with Jason McCarthy, senior managing director and head of biotechnology research at Maxim Group on June 22 at 9:00am ET.

This conference will be live on M-Vest. To attend, sign up to become an M-Vest member and register .

About Femasys

Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed in the United States include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit or follow us on , , and .

Contacts:

Investors

Chuck Padala

LifeSci Advisors, LLC

917-741-7792

Femasys Inc.

Investor Contact:

Media Contact:



EN
14/06/2023

Underlying

FEMYFEMASYS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FEMASYS INC

 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnost...

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device -- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its FemVue Controlled device, an innovat...

December 18, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces Third Quarter Financial Results for 2025

Femasys Announces Third Quarter Financial Results for 2025 – FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the third quarter of 2025. Corporate Highlights from 3Q 2025 Announced second partner order for Fem...

November 14, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Advances Global Growth with Second Partner Order for FemBloc® ...

Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe -- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and...

November 10, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and...

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million -- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ women’s health mission -- ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovat...

November 3, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces Initiation of Post-Market Surveillance Study for Fem...

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe --Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the commencement of a post-market surveillance (PMS) clinical study for its CE-marked FemBloc Permanent Birth Control. This study is being conducted in accordance wit...

October 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch